Navigation Links
Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
Date:3/15/2011

SAN DIEGO, March 15, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent 7,906,489 which covers methods of Clostridium difficile infection (CDI) treatment with fidaxomicin.  The patent, which is eligible for listing in the U.S. Food and Drug Administration's Orange Book, also received a term adjustment of an additional 762 days for the USPTO's delay in the examination process which extends the patent term to March 2027.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

"The issuance of this patent provides strong intellectual property protection for fidaxomicin, enhancing our drug candidate's present value," said Pedro Lichtinger, President and CEO of Optimer.  "Fidaxomicin is now protected by four issued patents and we are continuing our efforts to expand our patent portfolio for this important medical innovation."

Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment CDI. In two Phase 3 trials, fidaxomicin was equally effective in clinical cure when compared to vancomycin, the only FDA approved product for CDI.  Most importantly, fidaxomicin reduced the risk of recurrence by 47% compared to vancomycin.  Optimer has filed marketing applications in the United States and the European Union for fidaxomicin for the treatment of CDI and for reducing the risk of recurrence when used for treatment of initial CDI.

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fid
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sep. 04, 2015 ... the addition of the "Stability Testing of Pharmaceuticals ... their offering. By attending this comprehensive two ... to design efficient stability studies that are suitable for ... appropriate stability studies and manage stability samples and facilities ...
(Date:9/4/2015)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), ... of new cancer therapies, today announced its financial results ... provided an overview of recent Company highlights and expected ... host a business update conference call and live webcast ...
(Date:9/3/2015)... , Sept. 3, 2015  Cipla, a global ... the everyday needs of all patients, today announced that ... agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc., ... certain closing conditions, is valued at $550 million and ... from these transactions is over $200 million for the ...
Breaking Medicine Technology:Stability Testing of Pharmaceuticals: 2 Day Seminar - London, UK - December 2-3, 2015 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 3DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 4DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 5DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 6DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 7DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 8Cipla to acquire 100% of generic businesses in US for $550M 2Cipla to acquire 100% of generic businesses in US for $550M 3Cipla to acquire 100% of generic businesses in US for $550M 4Cipla to acquire 100% of generic businesses in US for $550M 5
(Date:9/4/2015)... ... September 04, 2015 , ... Scalability Experts ... the Year” awards at this year’s Microsoft Worldwide Partner Conference that was held ... the Year” Award Winner for Data Platform services, the 2015 HP and Microsoft ...
(Date:9/4/2015)... ... September 04, 2015 , ... San ... available at CitiDent. CEREC is a newer method for creating restorations through innovative ... patients by eliminating the need for multiple appointments, CEREC produces restorations with total ...
(Date:9/4/2015)... ... September 04, 2015 , ... Mike Day, a former Navy SEAL ... in the Ironman World Championships in Kona on October 10th. , Mike is running ... Injury (TBI) through combat and the cutting-edge treatments that restore their quality of life. ...
(Date:9/4/2015)... ... September 04, 2015 , ... Bio-Logic Aqua® Research, ... devices, announced its only mission and research focus: Water Life Science®. In the ... body water evaporation is becoming dangerously accelerated. As a result of the global ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... on: the microbiome taking place in Hollywood, Florida October 9-10, 2015 at the ... Speakers at the 2015 symposium are doctors and researchers at the top of ...
Breaking Medicine News(10 mins):Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2
... to temporary and later irreversible loss, experts say , MONDAY, ... leaving themselves open to temporary changes in hearing, which over ... , Scientists already know that at work, exposure to harmful ... that go on too long -- can eventually lead ...
... problem had higher levels of BPA, but study can,t ... News) -- There may be more troubling news about ... polycystic ovary syndrome have higher levels of the chemical ... of women with polycystic ovary syndrome (PCOS) develop multiple ...
... common hormone imbalance in women of reproductive age, may be ... found in many plastic household items, according to a new ... Society,s 92nd Annual Meeting in San Diego. The study ... associated with higher levels of male hormones in the blood ...
... at the Johns Hopkins Berman Institute of Bioethics says a ... the donation and banking of human biological material, one that ... and address donor expectations before research begins. In ... Me? Reflections on The Immortal Life of Henrietta Lacks and ...
... finds at least 4 to 6 months of exclusive ... Breast-feeding seems to provide an immune system boost ... in babies, according to new research. , Babies who ... until they were 6 months old, had a reduced ...
... Today the International and American Associations for Dental Research ... remains the number one journal of 64 journal published in ... new 2009 Five-Year Scientific Impact Factor (SIF) rankings, published by ... the JDR,s Five-Year SIF increased from 3.966 to 4.195. ...
Cached Medicine News:Health News:MP3 Players Might Harm Hearing 2Health News:MP3 Players Might Harm Hearing 3Health News:Plastics Chemical BPA Tied to Ovarian Cysts 2Health News:Plastics Chemical BPA Tied to Ovarian Cysts 3Health News:Women with polycystic ovary syndrome have higher BPA blood levels 2Health News:Scholar calls for a new legal, ethical framework for research with human tissue specimens 2Health News:Scholar calls for a new legal, ethical framework for research with human tissue specimens 3Health News:Scholar calls for a new legal, ethical framework for research with human tissue specimens 4Health News:Breast Milk Reduces Infections in Babies 2Health News:Breast Milk Reduces Infections in Babies 3Health News:JDR increases its 5-Year SIF and remains number one dental journal of 64 in its category 2
... Pro Professional Hemoglobin Testing System consists of ... strips, used in measuring total hemoglobin, from ... Pro provides the precision, accuracy and cost ... Pro Professional Hemoglobin Testing System is portable ...
... a fully automated analyzer that requires no ... by the operator. The Variant II sampling ... It reads the bar code, samples from ... specimen into the chromatographic station for analysis. ...
... Advia 70 hematology system delivers ... differential. Designed for speed and ... combines cost-effectiveness with impressive productivity. ... either on its own or ...
AcT 5diff OV enables low-volume labs to advance to 5-part differential analysis at an affordable price. This analyzer delivers accurate test results and a user-friendly software interface in a compac...
Medicine Products: